| Completed | Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers Healthy | EARLY_Phase 1 | 2018-03-05 |
| Terminated | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic M Melanoma | Phase 2 | 2017-12-08 |
| Completed | Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers Healthy | Phase 1 | 2017-11-21 |
| Terminated | Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunothe Pancreatic Cancer | — | 2017-09-01 |
| Completed | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors Solid Tumor | Phase 1 | 2017-06-29 |
| Completed | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leu Acute Myeloid Leukemia | Phase 1 | 2016-07-01 |
| Terminated | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent | Phase 1 | 2016-01-01 |
| Completed | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primar Glioblastoma Multiforme, Glioma, Gliosarcoma | Phase 1 | 2015-10-01 |
| Terminated | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors Solid Tumors | Phase 1 | 2015-10-01 |
| Terminated | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epit Ovarian Cancer | Phase 1 / Phase 2 | 2015-07-01 |
| Completed | Immunotherapy Study for Metastatic Renal Cell Cancer Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma | Phase 1 | 2015-05-01 |
| Terminated | Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors Advanced Solid Tumor Malignancy | Phase 1 / Phase 2 | 2015-04-01 |
| Terminated | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 2 | 2015-04-01 |
| Completed | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreat Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | 2014-08-01 |
| Completed | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | 2014-07-01 |
| Completed | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Metastatic Renal Cell Carcinoma | Phase 2 | 2014-07-01 |
| Terminated | Immunotherapy Study for Patients With Stage IV Melanoma Stage IV Melanoma, Metastatic Melanoma | Phase 2 | 2014-06-01 |
| Completed | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Glioblastoma Multiforme, Glioma, Gliosarcoma | Phase 1 / Phase 2 | 2014-03-01 |
| Terminated | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm | Phase 3 | 2013-05-01 |
| Completed | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2013-02-01 |
| Terminated | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent | Phase 2 / Phase 3 | 2013-02-01 |
| Completed | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer | Phase 2 | 2011-06-01 |
| Completed | Immunotherapy Study for Surgically Resected Pancreatic Cancer Pancreatic Cancer | Phase 3 | 2010-04-01 |
| Withdrawn | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. Cancer, Ovarian Cancer, Solid Tumor | Phase 2 | 2008-09-01 |
| Terminated | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors Breast Cancer, Lung Cancer, Melanoma | Phase 1 | 2008-08-01 |
| Terminated | Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2008-01-01 |
| Completed | Vaccine Study for Surgically Resected Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2007-12-01 |
| Terminated | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Phase 2 | 2007-01-01 |
| Completed | Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Cancer, Solid Tumor | Phase 1 / Phase 2 | 2006-05-01 |
| Completed | Vaccine Treatment for Advanced Malignant Melanoma Malignant Melanoma | Phase 1 / Phase 2 | 2006-03-01 |
| Completed | Vaccine Treatment for Surgically Resected Pancreatic Cancer Pancreatic Cancer | Phase 1 / Phase 2 | 2005-11-01 |
| Completed | Vaccine Treatment for Hormone Refractory Prostate Cancer Prostate Cancer | Phase 1 / Phase 2 | 2005-03-01 |
| Terminated | Vaccine Treatment for Advanced Breast Cancer Breast Cancer | Phase 1 / Phase 2 | 2004-08-01 |
| Completed | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2003-11-01 |